Consistent with our experimental findings, a recent study has shown that treatment with tocilizumab, an anti-IL6-R antibody, resulted in decreased fractions of monocytic MDSCs in the blood of patients with severe COVID-19 (65). This evidence concerns the gene IL6R and COVID-19.